2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Category: Publication
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors
Cancer Immunology Research
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
Cell Reports Medicine
Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody™), in metastatic castration resistant prostate cancer patients
American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) San Francisco, CA February 16-18, 2023.
LAVA-051, a novel bispecific gamma-delta T-cell engager (Gammabody™), in relapsed/refractory MM and CLL: pharmacodynamic and early clinical data
Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager, confirmed in the clinical setting
Submitted for presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Frontiers in Immunology publication, Saura-Esteller, et al.
Phase I dose escalation of LAVA-051, a novel bispecific γδ-T cell engager (Gammabody™), in relapsed/refractory hematological malignancies
European Hematological Association (EHA) 2022 Congress presentation Broijl, et al.
Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager (Gammabody™), in relapsed/refractory hematological malignancies
2022 American Society of Clinical Oncology (ASCO) Annual Meeting presentation
Brojil, et al.
Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d
Roeland Lameris, Jurjen M Ruben, Iris de Weerdt, Rob Roovers, Arnon P Kater, Thilo Riedl, Victoria Iglesias, Benjamin Winograd, Ton EP Adang, Tanja D de Gruijl, Paul WHI Parren, Hans J van der Vliet